Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection

E-resources

Peer reviewed

Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection

Borque-Fernando, Á; Zapatero, A; Manneh, R; Alonso-Gordoa, T; Couñago, F; Domínguez-Esteban, M; López-Valcárcel, M; Rodríguez-Antolín, A; Sala-González, N; Sanmamed, N; Maroto, P

Actas urológicas españolas (English ed.), 2024-May-11

Journal Article

The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme